Findings from Harvard University in bone cancer reported
2007 SEP 17 -- A new study, "Are fibula strut allografts a reliable alternative for periarticular reconstruction after curettage for bone tumors," is now available. According to recent research published in the journal Clinical Orthopaedics and Related Research, "Bone tumors occurring in periarticular locations may cause a substantial risk of subchondral fracture and collapse. Poly-methylmethacrylate has been used for reconstruction in these instances because of its immediate structural stability." "Allogeneic graft allows for biologic incorporation and remodeling, but it takes longer. Adding a fibula strut graft to the construct seems to provide structural stability during incorporation of the particulate graft. Seventeen of 22 (77.3%) patients returned to their full preoperative level of function after this procedure," wrote P.J. Buecker and colleagues, Harvard University. The researchers concluded: "We believe adding fibula strut to particulate allograft when using the buttress technique provides structural integrity and biologically active reconstruction, while maintaining a recurrence rate similar to those described for other reconstruction techniques." Buecker and colleagues published their study in Clinical Orthopaedics and Related Research (Are fibula strut allografts a reliable alternative for periarticular reconstruction after curettage for bone tumors? Clinical Orthopaedics and Related Research, 2007;461():170-4). For additional information, contact P.J. Buecker, Children's Hospital Boston, Harvard Medical School, Beth-Israel Deaconess Medical Center, Boston, MA USA.. The publisher's contact information for the journal Clinical Orthopaedics and Related Research is: Lippincott Williams & Wilkins, 530 Walnut St., Philadelphia, PA 19106-3621, USA. Keywords: United States, Boston, Bone Cancer, Bone Tumors, Curettage, Hematology, Oncology, Surgery. This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2007, Clinical Oncology Week via NewsRx.com.
|